HTRF IP-One assays detect the accumulation of inositol monophosphate, a stable downstream metabolite of IP3 induced by activation of a phospholipase C (PLC) cascade. This kit allows direct characterization of all types of compounds acting on Gq-coupled receptors in either adherent or suspension cells.

From high-throughput screening (HTS) to structure-activity relationships (SAR), IP-One has been shown to offer superior benefits over traditional assays

At Revvity, we regard "impossibility" as inspiration and "inability" as the driving force. Revvity offers health science solutions, cutting - edge technologies and professional services, with its business covering the entire end - to - end process of scientific research exploration, development, diagnosis, and treatment. Relying on years of in - depth cultivation in fields such as translational multi - omics technology, biomarker identification, imaging, disease prediction, screening, detection and diagnosis, and informatics, Revvity is using the power of technology to break through the boundaries of human potential.

In 2023, Revvity's turnover exceeded $2.7 billion. It has more than 11,000 employees worldwide and provides diverse services for customers such as pharmaceutical and biotechnology enterprises, diagnostic laboratories, scientific research institutions and government agencies. The company is a member of the S&P 500 Index, and its customers are spread across more than 190 countries and regions around the world.